The use of rasagiline in Parkinson's disease.
Rasagiline is a novel, potent, irreversible inhibitor of monoamine oxidative B developed for the symptomatic treatment of Parkinson's disease. The drug has shown efficacy in improving motor features in both early and advanced Parkinson's disease patients. The drug appears to be well tolerated and its once daily fixed dose formulation should make for excellent compliance. Rasagiline has also demonstrated important neuroprotective properties in both in vitro and in vivo laboratory studies. A provisional study of neuroprotection in a delayed start clinical trial of early PD patients has also suggested that this benefit may be translated to the clinic. Additional clinical trials are underway to confirm this.
Schapira
A H V
AH
University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK. a.schapira@medsch.ucl.ac.uk
D000818:Animals; D006801:Humans; D007189:Indans / Q000737:chemistry / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*
D007189:Indans; D018696:Neuroprotective Agents; C031967:rasagiline